Full Text
EE152 Cost-Effectiveness Modeling of Lurbinectedin As a Second-Line Therapy in Patients with Small Cell Lung Cancer (SCLC)

Abstract

Authors

W. Su B. Rengarajan D. Profant K. Mayo M. Groff G. Tremblay A.K. Ganti

Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×